Updated:
KabaFusion
KabaFusion is a pharmacist-owned home infusion company founded in 2010 by Dr. Sohail Masood, operating 27 pharmacies across the US.
KabaFusion
KabaFusion was founded in 2010 by pharmacist Dr. Sohail Masood. The company provides home infusion therapy, focusing on intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) treatments for autoimmune and neurological disorders. Pharmacies are accredited by the Accreditation Commission for HealthCare (ACHC) and the Utilization Review Accreditation Commission (URAC). The company operates 27 home infusion pharmacies and alternative-site infusion locations across the US, with service capabilities in over 40 states. Therapies cover neurology, immunology, oncology, infectious disease, and pain management. KabaFusion handles drug procurement, authorization, clinical management, and billing for infusion treatments. The firm also offers a patient app called myKabaFusion for care-team communication and electronic signing of documents. In February 2026, Nautic Partners completed a growth investment in KabaFusion, while Novo Holdings exited its investment. KabaFusion's clinician-led management team remains significant investors and continues to lead the company. The firm's corporate headquarters are split between Lexington, Massachusetts and Cerritos, California. The company is pharmacist-owned and structured as an operating company within a financial sponsor's portfolio, with management retaining meaningful equity post-investment. This governance model keeps clinical leadership aligned with operational decisions and capital allocation.
General information
Firm type
Family Office
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Lexington
Corporate office
Lexington, MA, United States
Additional offices
Cerritos, CA, United States
Principals
Sohail Masood
Founder
Nautic Partners
Growth Investor
Sector focus
Frequently asked questions
Who runs investment decisions at KabaFusion?
Dr. Sohail Masood founded the company and leads the clinician-led management team, which remains significant investors after Nautic Partners' growth investment in February 2026 (per firm press release, February 2026).
How does KabaFusion source proprietary deal flow?
KabaFusion operates as an operating company, not an investment fund. Deal flow comes through financial sponsors like Nautic Partners, which made a growth investment in the company in February 2026. Management does not publicly disclose external fundraising or direct investments.
Is KabaFusion structured as a single family office or does it operate more like a venture firm?
KabaFusion is a privately held operating company, not a family office or venture firm. It provides home infusion therapy services. The firm is pharmacist-owned and managed, with financial sponsors like Nautic Partners providing capital.
Does KabaFusion participate in fund commitments or only direct deals?
KabaFusion does not participate in fund commitments or direct external investments. It is an operating business that provides infusion therapy services, funded by its own operations and financial sponsor investments.
What investment stages does KabaFusion typically target?
KabaFusion does not target investment stages. It is a healthcare services company that delivers home infusion therapy to patients.
Which sectors does KabaFusion explicitly avoid?
KabaFusion does not invest in sectors; it operates exclusively in home infusion therapy, focusing on immunoglobulin and acute infusion treatments.
How is KabaFusion related to its parent or related vehicles?
KabaFusion is a portfolio company of Nautic Partners following the February 2026 growth investment. Novo Holdings previously held an investment that exited at that time (per firm press release, February 2026). Management retains significant equity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: